Your browser doesn't support javascript.
loading
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt, Andrew; Leonardi, Craig L; Gooderham, Melinda; Papp, Kim A; Philipp, Sandra; Wu, Jashin J; Igarashi, Atsuyuki; Flack, Mary; Geng, Ziqian; Wu, Tianshuang; Camez, Anne; Williams, David; Langley, Richard G.
Afiliação
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Leonardi CL; Department of Dermatology, St Louis University, St Louis, Missouri.
  • Gooderham M; Division of Dermatology, Department of Medicine, School of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Papp KA; SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Ontario, Canada.
  • Philipp S; K Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada.
  • Wu JJ; Department of Dermatology and Allergy/Institute of Medical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Igarashi A; Hautarztpraxis, Oranienburg, Germany.
  • Flack M; Dermatology Research and Education Foundation, Irvine, California.
  • Geng Z; Department of Dermatology, NTT Medical Center, Tokyo, Japan.
  • Wu T; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut.
  • Camez A; AbbVie Inc, North Chicago, Illinois.
  • Williams D; AbbVie Inc, North Chicago, Illinois.
  • Langley RG; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
JAMA Dermatol ; 156(6): 649-658, 2020 06 01.
Article em En | MEDLINE | ID: mdl-32267471

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Suspensão de Tratamento / Anticorpos Monoclonais Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Suspensão de Tratamento / Anticorpos Monoclonais Idioma: En Ano de publicação: 2020 Tipo de documento: Article